2–3 TIMES DAILY (ER ONCE)
ANTI-SEIZURE MEDICATION · FOCAL ≥10 Y · ABSENCE · ADULT MIGRAINE, MANIA
VALPROATE (Depakote DR/ER)
Formulations: DR 125, 250, 500 · ER 250, 500 · sprinkle 125 · caps 250 · soln 250 mg/5 mL · IV 100 mg/mL
GENERIC AVAILABLEMULTIPLE MECHANISMSBROAD$
With food. ER dose = DR × 1.08–1.2.
T½9–16 h
Steady state2–4 d
Works inDay 1 (IV load)
Missed doseWhen remembered; skip if the next dose is near. Never double.
Profile↑ Weight+ Mood– Cognition! Sedation! Bone→ SE clock pp. 6–7 · Switching p. 51
Mechanism · Broad: Na+ channel block, T-type Ca2+ inhibition, raised GABA (GABA-transaminase inhibition), HDAC inhibition.
Indication
FDA-approved: Focal, absence (simple and complex) seizures; migraine; mania.
Off-label: Myoclonic, GTC, LGS, SE (IV), younger children.
Can worsen: Not characteristic.
Dosing · Titrate weekly
| When | Dose | Notes |
| Start | 10–15 mg/kg/d | |
| Then | +5–10 mg/kg/d weekly | |
| Target | 750–2000 mg/d | Max 60 mg/kg/d |
| SE load | 40 mg/kg IV | Max 3000 mg over 10 min |
| IV maint. | Same daily dose | Div q6h |
RenalNo change; use free level.
HepaticContraindicated.
Serum level50–100 µg/mL; platelets fall >110 (F) / >135 (M). Free 5–15 (practice).
Abortive / Rescue YESSecond-line SE: 40 mg/kg IV (max 3000 mg) over 10 min (ESETT). Good choice in generalized or absence status.
Can’t swallow · Oral → IV1:1. Same total daily dose IV, divided q6h (label); infuse over 60 min.
Side effects & toxicity
Common: Tremor, weight gain, hair thinning, nausea, dose-related thrombocytopenia, menstrual irregularity, PCOS features. Serious: Boxed: hepatotoxicity (highest <2 y, polytherapy, POLG mitochondrial disease), pancreatitis, teratogenicity. Also hyperammonemic encephalopathy, coagulopathy, DRESS. Overdose: CNS depression, cerebral edema, hyperammonemia, metabolic acidosis, pancytopenia. L-carnitine 100 mg/kg IV; HD if level >900–1000 µg/mL or severe.
Warnings · Read by tier
1Contraindicated · do not use: Hypersensitivity to valproate; hepatic disease or significant dysfunction; POLG mutation; suspected POLG disorder <2 y; urea-cycle disorders; migraine use in pregnancy, or in women of childbearing potential without effective contraception.
2Avoid / prefer alternative: Anyone who may become pregnant, unless others fail and pregnancy prevention is in place; concurrent carbapenem antibiotics; children <2 y on polytherapy.
3Use with monitoring: LFTs, CBC + platelets at baseline and often in first 6 months; ammonia if lethargic or confused; weight; free level if albumin low; ASM suicidality class warning.
Pregnancy · Red / AvoidMCM ~10% (EURAP), NTD 1–2%, lower IQ, autism. Avoid unless nothing else works.
BreastfeedingLow transfer; compatible.
Key interactions · VPA affects other drugs
1. VPA raises lamotrigine (×2), phenobarbital, CBZ-epoxide, free phenytoin, rufinamide. Inhibits UGT, 2C9, epoxide hydrolase.
Other drugs → VPA: how other drugs change its levels. Carbapenems drop VPA 60–90% within 24 h. Inducers lower it. Aspirin displaces it. Topiramate: hyperammonemia.
Taper / stop: Taper over ≥2–4 weeks (−250–500 mg every 1–2 weeks).
Source: FDA Depakote / Depacon prescribing information. Verify against current label. Data current 26 Oct 2026. 40